The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

Estrogen is an important hormone in the body, especially for women, and its levels can rise due to various factors, resulting ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...

Adulterated protein supplements can lead to unintentional doping. This review outlines detection strategies and protective measures for athletes and clinicians.

Remibrutinib's approval for CSU highlights BTK inhibitors' expansion into immunology, offering a convenient oral alternative to injectable biologics. CSU is characterized by unpredictable hives due to ...

Cardiac rehabilitation (CR) is a proven intervention to improve cardiovascular health, offering benefits such as reduced ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...